Cardiovascular Medicine and Haematology articles for Imperial College London (ICL), United Kingdom (UK)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 93

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.17
Reproductive factors and the risk of incident peripheral arterial disease hospitalisation or death: A cohort study of UK Biobank participants 0.17
17 2.38
Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials 0.06
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial 0.04
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.02
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial 0.04
Lower airway immunophenotyping in severe preschool wheeze reveals distinct clusters described by heterogeneity in neutrophil phenotypes 0.89
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.06
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.04
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.06
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.13
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.06
Non-Coding DNA Variants Increase the Genetic Diagnostic Yield in Primary Ciliary Dyskinesia. 0.09
Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome 0.46
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.00
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.03
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.03
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study 0.31
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.05
2 0.46
The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis 0.36
Mortality Outcomes and ACE Inhibitor Use in Patients with Idiopathic Pulmonary Fibrosis 0.10
6 0.72
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study. 0.30
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.01
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes. 0.04
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. 0.08
The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. 0.28
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.02
1 0.03
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL. 0.03
1 0.17
TRPA1 mediates ozone-induced murine model of COPD through the Wnt5a/GSK-3β/β-catenin pathway 0.17
12 2.56
Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrate 0.18
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials 0.11
A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trial 0.00
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.05
The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk 0.01
Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study 0.24
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.03
Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study 0.81
Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study 0.04
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.01
First myocardial infarction: risk factors, symptoms, and medical therapy 0.07
Mode of revascularization for ischaemic cardiomyopathy: comparing apples with oranges? 1.00
1 0.17
A cohort study of forced vital capacity, airway obstruction, and survival in the multinational Burden of Obstructive Lung Disease study 0.17
1 0.22
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes 0.22
4 0.15
Digoxin in Patients With Symptomatic Rheumatic Heart Disease 0.01
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.03
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.02
Remote Screening for Asymptomatic Atrial Fibrillation 0.08
8 1.63
Focal and Diffuse Coronary Artery Disease Patterns and Placebo-Controlled Angina Relief With Percutaneous Coronary Intervention 0.94
A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO 0.10
Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation 0.03
Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals 0.08
Association Between Age and PCI Effectiveness in Stable CAD Secondary Analysis of ORBITA-2 0.36
Potent P2Y12 Inhibitor Monotherapy versus DAPT after PCI in Patients With and Without STEMI: NEO-MINDSET Substudy 0.02
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.01
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis 0.10
1 0.17
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.17
7 0.88
Gene-gene interactions between a LMNA variant and common polymorphisms drive early-onset atrial fibrillation 0.22
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.10
Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment 0.14
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.09
Cross-population GWAS and proteomics improve risk prediction and reveal mechanisms in atrial fibrillation 0.06
Connective tissue disorder and high risk pregnancy: a case series with personalised external aortic root support (PEARS) 0.19
Imbalanced TGFβ signalling and autophagy drive erythroid priming of hematopoietic stem cells in β-thalassemia 0.07
4 0.12
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.01
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.04
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.00
Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial 0.06
1 0.14
Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study 0.14
1 0.02
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.02
2 0.17
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension 0.13
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy 0.04
4 0.51
Differential effects of subcutaneous and sublingual immunotherapy on timothy grass–specific TH2 CD4+ T-cell subsets 0.17
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.24
Genetic characterization of preschool wheeze phenotypes 0.04
Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma 0.07
5 0.09
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study 0.01
Budesonide–formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial 0.02
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.01
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials 0.03
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial 0.01
7 0.19
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia 0.03
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage 0.00
Angiography-Derived Fractional Flow Reserve to Guide PCI 0.02
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction 0.06
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.05
Hypertonic Saline or Carbocisteine in Bronchiectasis 0.01
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes 0.01
7 2.48
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study 0.02
Impact of air pollution on lung function in cystic fibrosis over a decade in London: a UK CF Registry study 0.58
Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD 0.14
Understanding the bidirectional relationship between chronic respiratory disease and cardiovascular disease using genetic evidence 0.94
Time to diagnosis and long-term outcomes for adults presenting with breathlessness 0.22
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts 0.38
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.18

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.